Portola Pharmaceuticals Inc (PTLA): This Hedge Fund is Loading Up Following Stock’s Weakness

Page 7 of 12

Page 7 of 12 – SEC Filing
CUSIP No.
737010108
 
Page 10 of 12 Pages
(iii)
Sole power to dispose or to direct the disposition of:
All Reporting Persons – 0
(iv)
Shared power to dispose or to direct the disposition of:
Deerfield Mgmt, L.P. – 3,089,785
Deerfield Management Company, L.P. – 3,089,785
Deerfield Partners, L.P. –  1,340,437
Deerfield International Master Fund, L.P. – 1,706,011
Deerfield Special Situations Fund, L.P. – 43,337
James E. Flynn – 3,089,785
 
**See footnotes on cover pages which are incorporated by reference herein.
  
Item 5.
Ownership of Five Percent or Less of a Class.
 
     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following o.
 
 
 
 
Item 6.
Ownership of More Than Five Percent on Behalf of Another Person.
 
     If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
 
 
N/A
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
 
     If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
 
 
N/A

 

Item 8.
Identification and Classification of Members of the Group.
 
     If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.
 
 
See Exhibit B
 
Item 9.
Notice of Dissolution of Group.
 
     Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
 
N/A

Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Page 7 of 12